Skip to main content
Top
Published in: Journal of General Internal Medicine 11/2010

01-11-2010 | Reviews

Effect of Verification Bias on the Sensitivity of Fecal Occult Blood Testing: a Meta-Analysis

Authors: Alan S. Rosman, MD, Mark A. Korsten, MD

Published in: Journal of General Internal Medicine | Issue 11/2010

Login to get access

Abstract

OBJECTIVES

There is controversy regarding the sensitivity of fecal occult blood tests (FOBT) for detecting colorectal cancer. Many of the published studies failed to correct for verification bias which may have increased the sensitivity.

METHODS

A meta-analysis of published studies evaluating the sensitivity and specificity of chemical-based FOBT for colorectal cancer was performed. Studies were included if both cancer and control subjects underwent confirmatory testing. We also included studies that attempted to correct for verification bias by either performing colonoscopy on all subjects regardless of the FOBT result or by using longitudinal follow-up. We then compared the sensitivity, specificity, and other diagnostic characteristics of the studies that attempted to correct for verification (n = 10) vs. those that did not correct for this bias (n = 19).

RESULTS

The pooled sensitivity of guaiac-based FOBT for colorectal cancer of studies without verification bias was significantly lower than those studies with this bias [0.36 (95% CI 0.25-0.47) vs. 0.70 (95% CI 0.60–0.80), p = 0.001]. The pooled specificity of the studies without verification bias was higher [0.96 (95% CI 0.94–0.97) vs. 0.88 (95% CI 0.84–0.91), p < 0.005]. There was no significant difference in the area under the summary receiver operating characteristic curves. More sensitive chemical-based FOBT methods (e.g., Hemoccult® SENSA®) had a higher sensitivity but a lower specificity than standard guaiac methods.

CONCLUSIONS

The sensitivity of guaiac-based FOBT for colorectal cancer has been overestimated as a result of verification bias. This test may not be sensitive enough to serve as an effective screening option for colorectal cancer.
Literature
1.
2.
go back to reference Allison JE. Review article: faecal occult blood testing for colorectal cancer. Aliment Pharmacol Ther. 1998;12:1–10.CrossRefPubMed Allison JE. Review article: faecal occult blood testing for colorectal cancer. Aliment Pharmacol Ther. 1998;12:1–10.CrossRefPubMed
3.
go back to reference Centers for Disease Control and Prevention. Use of colorectal cancer tests-United States, 2002, 2004, and 2006. MMWR Morb Mortal Wkly Rep. 2008;57:253–8. Centers for Disease Control and Prevention. Use of colorectal cancer tests-United States, 2002, 2004, and 2006. MMWR Morb Mortal Wkly Rep. 2008;57:253–8.
4.
go back to reference Greenwald B. From guaiac to immune fecal occult blood tests: the emergence of technology in colorectal cancer screening. Gastroenterol Nurs. 2005;28:90–6.CrossRefPubMed Greenwald B. From guaiac to immune fecal occult blood tests: the emergence of technology in colorectal cancer screening. Gastroenterol Nurs. 2005;28:90–6.CrossRefPubMed
5.
go back to reference Ouyang DL, Chen JJ, Getzenberg RH, Schoen RE. Noninvasive testing for colorectal cancer: a review. Am J Gastroenterol. 2005;100:1393–403.CrossRefPubMed Ouyang DL, Chen JJ, Getzenberg RH, Schoen RE. Noninvasive testing for colorectal cancer: a review. Am J Gastroenterol. 2005;100:1393–403.CrossRefPubMed
6.
go back to reference Crespi M, Lisi D. Is colorectal cancer screening by fecal occult blood feasible? Ann Oncol. 2002;13:47–50.CrossRefPubMed Crespi M, Lisi D. Is colorectal cancer screening by fecal occult blood feasible? Ann Oncol. 2002;13:47–50.CrossRefPubMed
7.
go back to reference Bond JH. Fecal occult blood test screening for colorectal cancer. Gastrointest Endosc Clin N Am. 2002;12:11–21.CrossRefPubMed Bond JH. Fecal occult blood test screening for colorectal cancer. Gastrointest Endosc Clin N Am. 2002;12:11–21.CrossRefPubMed
8.
go back to reference Burch JA, Soares-Weiser K, St John DJB, et al. Diagnostic accuracy of faecal occult blood tests used in screening for colorectal cancer: a systematic review. J Med Screen. 2007;14:132–7.CrossRefPubMed Burch JA, Soares-Weiser K, St John DJB, et al. Diagnostic accuracy of faecal occult blood tests used in screening for colorectal cancer: a systematic review. J Med Screen. 2007;14:132–7.CrossRefPubMed
10.
go back to reference Simon JB. Fecal occult blood testing: clinical value and limitations. Gastroenterologist. 1998;6:66–78.PubMed Simon JB. Fecal occult blood testing: clinical value and limitations. Gastroenterologist. 1998;6:66–78.PubMed
11.
go back to reference Winawer SJ, Schottenfeld D, Flehinger BJ. Colorectal cancer screening. J Natl Cancer Inst. 1991;83:243–53.CrossRefPubMed Winawer SJ, Schottenfeld D, Flehinger BJ. Colorectal cancer screening. J Natl Cancer Inst. 1991;83:243–53.CrossRefPubMed
13.
go back to reference Begg CB, Greenes RA. Assessment of diagnostic tests when disease verification is subject to selection bias. Biometrics. 1983;39:207–15.CrossRefPubMed Begg CB, Greenes RA. Assessment of diagnostic tests when disease verification is subject to selection bias. Biometrics. 1983;39:207–15.CrossRefPubMed
14.
go back to reference Choi BC. Sensitivity and specificity of a single diagnostic test in the presence of work-up bias. J Clin Epidemiol. 1992;45:581–6.CrossRefPubMed Choi BC. Sensitivity and specificity of a single diagnostic test in the presence of work-up bias. J Clin Epidemiol. 1992;45:581–6.CrossRefPubMed
15.
go back to reference Greenes RA, Begg CB. Assessment of diagnostic technologies. Methodology for unbiased estimation from samples of selectively verified patients. Invest Radiol. 1985;20:751–6.CrossRefPubMed Greenes RA, Begg CB. Assessment of diagnostic technologies. Methodology for unbiased estimation from samples of selectively verified patients. Invest Radiol. 1985;20:751–6.CrossRefPubMed
16.
go back to reference Punglia RS, D'Amico AV, Catalona WJ, Roehl KA, Kuntz KM. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med. 2003;349:335–42.CrossRefPubMed Punglia RS, D'Amico AV, Catalona WJ, Roehl KA, Kuntz KM. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med. 2003;349:335–42.CrossRefPubMed
17.
go back to reference Begg CB, McNeil BJ. Assessment of radiologic tests: control of bias and other design considerations. Radiology. 1988;167:565–9.PubMed Begg CB, McNeil BJ. Assessment of radiologic tests: control of bias and other design considerations. Radiology. 1988;167:565–9.PubMed
18.
go back to reference Dinnes J, Deeks J, Kirby J, Roderick P. A methodological review of how heterogeneity has been examined in systematic reviews of diagnostic test accuracy. Health Technol Assess. 2005;9:1–113. Dinnes J, Deeks J, Kirby J, Roderick P. A methodological review of how heterogeneity has been examined in systematic reviews of diagnostic test accuracy. Health Technol Assess. 2005;9:1–113.
19.
20.
21.
go back to reference Takkouche B, Cadarso-Suarez C, Spiegelman D. Evaluation of old and new tests of heterogeneity in epidemiologic meta-analysis. Am J Epidemiol. 1999;150:206–15.PubMed Takkouche B, Cadarso-Suarez C, Spiegelman D. Evaluation of old and new tests of heterogeneity in epidemiologic meta-analysis. Am J Epidemiol. 1999;150:206–15.PubMed
22.
go back to reference Leeflang MMG, Deeks JJ, Gatsonis C, Bossuyt PMM, Cochrane Diagnostic Test Accuracy Working G. Systematic reviews of diagnostic test accuracy. Ann Intern Med. 2008;149:889–97.PubMed Leeflang MMG, Deeks JJ, Gatsonis C, Bossuyt PMM, Cochrane Diagnostic Test Accuracy Working G. Systematic reviews of diagnostic test accuracy. Ann Intern Med. 2008;149:889–97.PubMed
23.
go back to reference Hyde CJ, Stanworth SJ, Murphy MF. Can you see the wood for the trees? Making sense of forest plots in systematic reviews 2. Analysis of the combined results from the included studies. Transfusion. 2008;48:580–3.CrossRefPubMed Hyde CJ, Stanworth SJ, Murphy MF. Can you see the wood for the trees? Making sense of forest plots in systematic reviews 2. Analysis of the combined results from the included studies. Transfusion. 2008;48:580–3.CrossRefPubMed
24.
go back to reference Goodacre S, Sampson F, Thomas S, van Beek E, Sutton A. Systematic review and meta-analysis of the diagnostic accuracy of ultrasonography for deep vein thrombosis. BMC Med Imaging. 2005;5:6.CrossRefPubMed Goodacre S, Sampson F, Thomas S, van Beek E, Sutton A. Systematic review and meta-analysis of the diagnostic accuracy of ultrasonography for deep vein thrombosis. BMC Med Imaging. 2005;5:6.CrossRefPubMed
25.
go back to reference Lijmer JG, Bossuyt PMM, Heisterkamp SH. Exploring sources of heterogeneity in systematic reviews of diagnostic tests. Stat Med. 2002;21:1525–37.CrossRefPubMed Lijmer JG, Bossuyt PMM, Heisterkamp SH. Exploring sources of heterogeneity in systematic reviews of diagnostic tests. Stat Med. 2002;21:1525–37.CrossRefPubMed
26.
go back to reference Irwig L, Macaskill P, Glasziou P, Fahey M. Meta-analytic methods for diagnostic test accuracy. J Clin Epidemiol. 1995;48:119–30.CrossRefPubMed Irwig L, Macaskill P, Glasziou P, Fahey M. Meta-analytic methods for diagnostic test accuracy. J Clin Epidemiol. 1995;48:119–30.CrossRefPubMed
27.
go back to reference Irwig L, Tosteson AN, Gatsonis C, et al. Guidelines for meta-analyses evaluating diagnostic tests. Ann Intern Med. 1994;120:667–76.PubMed Irwig L, Tosteson AN, Gatsonis C, et al. Guidelines for meta-analyses evaluating diagnostic tests. Ann Intern Med. 1994;120:667–76.PubMed
28.
go back to reference Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med. 1993;12:1293–316.PubMed Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med. 1993;12:1293–316.PubMed
29.
go back to reference Rosman AS, Korsten MA. Application of summary receiver operating characteristics (sROC) analysis to diagnostic clinical testing. Adv Med Sci. 2007;52:76–82.PubMed Rosman AS, Korsten MA. Application of summary receiver operating characteristics (sROC) analysis to diagnostic clinical testing. Adv Med Sci. 2007;52:76–82.PubMed
30.
go back to reference Walter SD. Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data. Stat Med. 2002;21:1237–56.CrossRefPubMed Walter SD. Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data. Stat Med. 2002;21:1237–56.CrossRefPubMed
31.
go back to reference Crowley ML, Freeman LD, Mottet MD, et al. Sensitivity of guaiac-impregnated cards for the detection of colorectal neoplasia. J Clin Gastroenterol. 1983;5:127–30.CrossRefPubMed Crowley ML, Freeman LD, Mottet MD, et al. Sensitivity of guaiac-impregnated cards for the detection of colorectal neoplasia. J Clin Gastroenterol. 1983;5:127–30.CrossRefPubMed
32.
go back to reference Farrands PA, O'Regan D, Taylor I. An assessment of occult blood testing to determine which patients with large bowel symptoms require urgent investigation. Br J Surg. 1985;72:835–7.CrossRefPubMed Farrands PA, O'Regan D, Taylor I. An assessment of occult blood testing to determine which patients with large bowel symptoms require urgent investigation. Br J Surg. 1985;72:835–7.CrossRefPubMed
33.
go back to reference Greenberg PD, Bertario L, Gnauck R, et al. A prospective multicenter evaluation of new fecal occult blood tests in patients undergoing colonoscopy. Am J Gastroenterol. 2000;95:1331–8.CrossRefPubMed Greenberg PD, Bertario L, Gnauck R, et al. A prospective multicenter evaluation of new fecal occult blood tests in patients undergoing colonoscopy. Am J Gastroenterol. 2000;95:1331–8.CrossRefPubMed
34.
go back to reference Guittet L, Bouvier V, Mariotte N, et al. Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. Gut. 2007;56:210–4.CrossRefPubMed Guittet L, Bouvier V, Mariotte N, et al. Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. Gut. 2007;56:210–4.CrossRefPubMed
35.
go back to reference Hoepffner N, Shastri YM, Hanisch E, et al. Comparative evaluation of a new bedside faecal occult blood test in a prospective multicentre study. Aliment Pharmacol Ther. 2006;23:145–54.CrossRefPubMed Hoepffner N, Shastri YM, Hanisch E, et al. Comparative evaluation of a new bedside faecal occult blood test in a prospective multicentre study. Aliment Pharmacol Ther. 2006;23:145–54.CrossRefPubMed
36.
go back to reference Hope RL, Chu G, Hope AH, Newcombe RG, Gillespie PE, Williams SJ. Comparison of three faecal occult blood tests in the detection of colorectal neoplasia. Gut. 1996;39:722–5.CrossRefPubMed Hope RL, Chu G, Hope AH, Newcombe RG, Gillespie PE, Williams SJ. Comparison of three faecal occult blood tests in the detection of colorectal neoplasia. Gut. 1996;39:722–5.CrossRefPubMed
37.
go back to reference Jeanson A, Jamart J, Maisin JM, et al. Assessment of the new immunological test Hemoblot for detecting occult blood in faeces. Eur J Cancer Prev. 1994;3:407–12.CrossRefPubMed Jeanson A, Jamart J, Maisin JM, et al. Assessment of the new immunological test Hemoblot for detecting occult blood in faeces. Eur J Cancer Prev. 1994;3:407–12.CrossRefPubMed
38.
go back to reference Kimmig JM, Strauch M, Hallen M. Negative Haemoccult test in malignant and premalignant lesions of the colon. Validation of the Haemoccult test with total colonoscopy. Endoscopy. 1989;21:136–40.CrossRefPubMed Kimmig JM, Strauch M, Hallen M. Negative Haemoccult test in malignant and premalignant lesions of the colon. Validation of the Haemoccult test with total colonoscopy. Endoscopy. 1989;21:136–40.CrossRefPubMed
39.
go back to reference Leicester RJ, Lightfoot A, Millar J, Colin-Jones DG, Hunt RH. Accuracy and value of the Hemoccult test in symptomatic patients. Br Med J (Clin Res Ed). 1983;286:673–4.CrossRef Leicester RJ, Lightfoot A, Millar J, Colin-Jones DG, Hunt RH. Accuracy and value of the Hemoccult test in symptomatic patients. Br Med J (Clin Res Ed). 1983;286:673–4.CrossRef
40.
go back to reference Lenhard K, Bommer GT, Asutay S, et al. Analysis of promoter methylation in stool: a novel method for the detection of colorectal cancer. Clin Gastroenterol Hepatol. 2005;3:142–9.CrossRefPubMed Lenhard K, Bommer GT, Asutay S, et al. Analysis of promoter methylation in stool: a novel method for the detection of colorectal cancer. Clin Gastroenterol Hepatol. 2005;3:142–9.CrossRefPubMed
41.
go back to reference Li S, Wang H, Hu J, et al. New immunochemical fecal occult blood test with two-consecutive stool sample testing is a cost-effective approach for colon cancer screening: results of a prospective multicenter study in Chinese patients. Int J Cancer. 2006;118:3078–83.CrossRefPubMed Li S, Wang H, Hu J, et al. New immunochemical fecal occult blood test with two-consecutive stool sample testing is a cost-effective approach for colon cancer screening: results of a prospective multicenter study in Chinese patients. Int J Cancer. 2006;118:3078–83.CrossRefPubMed
42.
go back to reference Miyoshi H, Oka M, Sugi K, Saitoh O, Katsu K, Uchida K. Accuracy of detection of colorectal neoplasia using an immunochemical occult blood test in symptomatic referred patients: comparison of retrospective and prospective studies. Intern Med. 2000;39:701–6.CrossRefPubMed Miyoshi H, Oka M, Sugi K, Saitoh O, Katsu K, Uchida K. Accuracy of detection of colorectal neoplasia using an immunochemical occult blood test in symptomatic referred patients: comparison of retrospective and prospective studies. Intern Med. 2000;39:701–6.CrossRefPubMed
43.
go back to reference Nakama H, Kamijo N. Accuracy of immunological fecal occult blood testing for colorectal cancer screening. Prev Med. 1994;23:309–13.CrossRefPubMed Nakama H, Kamijo N. Accuracy of immunological fecal occult blood testing for colorectal cancer screening. Prev Med. 1994;23:309–13.CrossRefPubMed
44.
go back to reference Niv Y, Sperber AD. Sensitivity, specificity, and predictive value of fecal occult blood testing (Hemoccult II) for colorectal neoplasia in symptomatic patients: a prospective study with total colonoscopy. Am J Gastroenterol. 1995;90:1974–7.PubMed Niv Y, Sperber AD. Sensitivity, specificity, and predictive value of fecal occult blood testing (Hemoccult II) for colorectal neoplasia in symptomatic patients: a prospective study with total colonoscopy. Am J Gastroenterol. 1995;90:1974–7.PubMed
45.
go back to reference Norfleet RG. Effect of diet on fecal occult blood testing in patients with colorectal polyps. Dig Dis Sci. 1986;31:498–501.CrossRefPubMed Norfleet RG. Effect of diet on fecal occult blood testing in patients with colorectal polyps. Dig Dis Sci. 1986;31:498–501.CrossRefPubMed
46.
go back to reference Pye G, Marks CG, Martin S, Marks V, Jackson J, Hardcastle JD. An evaluation of Fecatwin/Feca EIA; a faecal occult blood test for detecting colonic neoplasia. Eur J Surg Oncol. 1989;15:446–8.PubMed Pye G, Marks CG, Martin S, Marks V, Jackson J, Hardcastle JD. An evaluation of Fecatwin/Feca EIA; a faecal occult blood test for detecting colonic neoplasia. Eur J Surg Oncol. 1989;15:446–8.PubMed
47.
go back to reference Thomas WM, Hardcastle JD, Jackson J, Pye G. Chemical and immunological testing for faecel occult blood: a comparison of two tests in symptomatic patients. Br J Cancer. 1992;65:618–20.PubMed Thomas WM, Hardcastle JD, Jackson J, Pye G. Chemical and immunological testing for faecel occult blood: a comparison of two tests in symptomatic patients. Br J Cancer. 1992;65:618–20.PubMed
48.
go back to reference Tibble J, Sigthorsson G, Foster R, Sherwood R, Fagerhol M, Bjarnason I. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut. 2001;49:402–8.CrossRefPubMed Tibble J, Sigthorsson G, Foster R, Sherwood R, Fagerhol M, Bjarnason I. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut. 2001;49:402–8.CrossRefPubMed
49.
go back to reference Williams JA, Hunter R, Coles ME, Thomas DW, Huber TW. An assessment of an immunochemical test for human haemoglobin in the detection of colonic polyps. Aust N Z J Surg. 1985;55:485–8.CrossRefPubMed Williams JA, Hunter R, Coles ME, Thomas DW, Huber TW. An assessment of an immunochemical test for human haemoglobin in the detection of colonic polyps. Aust N Z J Surg. 1985;55:485–8.CrossRefPubMed
50.
go back to reference Williams JA, Hunter R, Smith M, Coles ME, Hubert TW, Thomas DW. Evaluation of an immunological test for occult bleeding from colorectal neoplasia. Aust N Z J Surg. 1982;52:617–21.CrossRefPubMed Williams JA, Hunter R, Smith M, Coles ME, Hubert TW, Thomas DW. Evaluation of an immunological test for occult bleeding from colorectal neoplasia. Aust N Z J Surg. 1982;52:617–21.CrossRefPubMed
51.
go back to reference Ahlquist DA, Sargent DJ, Loprinzi CL, et al. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med. 2008;149:441–50.PubMed Ahlquist DA, Sargent DJ, Loprinzi CL, et al. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med. 2008;149:441–50.PubMed
52.
go back to reference Allison JE, Feldman R, Tekawa IS. Hemoccult screening in detecting colorectal neoplasm: sensitivity, specificity, and predictive value. Long-term follow-up in a large group practice setting. Ann Intern Med. 1990;112:328–33.PubMed Allison JE, Feldman R, Tekawa IS. Hemoccult screening in detecting colorectal neoplasm: sensitivity, specificity, and predictive value. Long-term follow-up in a large group practice setting. Ann Intern Med. 1990;112:328–33.PubMed
53.
go back to reference Allison JE, Tekawa IS, Ransom LJ, Adrain AL. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med. 1996;334:155–9.CrossRefPubMed Allison JE, Tekawa IS, Ransom LJ, Adrain AL. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med. 1996;334:155–9.CrossRefPubMed
54.
go back to reference Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME, Colorectal Cancer Study G. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med. 2004;351:2704–14.CrossRefPubMed Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME, Colorectal Cancer Study G. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med. 2004;351:2704–14.CrossRefPubMed
55.
go back to reference Kristinsson J, Nygaard K, Aadland E, et al. Screening of first degree relatives of patients operated for colorectal cancer: evaluation of fecal calprotectin vs. hemoccult II. Digestion. 2001;64:104–10.CrossRefPubMed Kristinsson J, Nygaard K, Aadland E, et al. Screening of first degree relatives of patients operated for colorectal cancer: evaluation of fecal calprotectin vs. hemoccult II. Digestion. 2001;64:104–10.CrossRefPubMed
56.
go back to reference Lieberman DA, Weiss DG, Veterans Affairs Cooperative Study G. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N Engl J Med. 2001;345:555–60.CrossRefPubMed Lieberman DA, Weiss DG, Veterans Affairs Cooperative Study G. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N Engl J Med. 2001;345:555–60.CrossRefPubMed
57.
go back to reference Murakami R, Otani T, Nakanishi K, et al. Diagnostic validity of fecal occult blood tests for detecting gastroenterological cancers. Jpn J Cancer Res. 1992;83:141–5.PubMed Murakami R, Otani T, Nakanishi K, et al. Diagnostic validity of fecal occult blood tests for detecting gastroenterological cancers. Jpn J Cancer Res. 1992;83:141–5.PubMed
58.
go back to reference Robinson MH, Kronborg O, Williams CB, et al. Faecal occult blood testing and colonoscopy in the surveillance of subjects at high risk of colorectal neoplasia. Br J Surg. 1995;82:318–20.CrossRefPubMed Robinson MH, Kronborg O, Williams CB, et al. Faecal occult blood testing and colonoscopy in the surveillance of subjects at high risk of colorectal neoplasia. Br J Surg. 1995;82:318–20.CrossRefPubMed
59.
go back to reference Sung JJY, Chan FKL, Leung WK, et al. Screening for colorectal cancer in Chinese: comparison of fecal occult blood test, flexible sigmoidoscopy, and colonoscopy. Gastroenterology. 2003;124:608–14.CrossRefPubMed Sung JJY, Chan FKL, Leung WK, et al. Screening for colorectal cancer in Chinese: comparison of fecal occult blood test, flexible sigmoidoscopy, and colonoscopy. Gastroenterology. 2003;124:608–14.CrossRefPubMed
60.
go back to reference Williams CB, Macrae FA, Bartram CI. A prospective study of diagnostic methods in adenoma follow-up. Endoscopy. 1982;14:74–8.CrossRefPubMed Williams CB, Macrae FA, Bartram CI. A prospective study of diagnostic methods in adenoma follow-up. Endoscopy. 1982;14:74–8.CrossRefPubMed
61.
go back to reference Levi Z, Hazazi R, Rozen P, Vilkin A, Waked A, Niv Y. A quantitative immunochemical faecal occult blood test is more efficient for detecting significant colorectal neoplasia than a sensitive guaiac test. Aliment Pharmacol Ther. 2006;23:1359–64.CrossRefPubMed Levi Z, Hazazi R, Rozen P, Vilkin A, Waked A, Niv Y. A quantitative immunochemical faecal occult blood test is more efficient for detecting significant colorectal neoplasia than a sensitive guaiac test. Aliment Pharmacol Ther. 2006;23:1359–64.CrossRefPubMed
62.
go back to reference Smith A, Young GP, Cole SR, Bampton P. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia. Cancer. 2006;107:2152–9.CrossRefPubMed Smith A, Young GP, Cole SR, Bampton P. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia. Cancer. 2006;107:2152–9.CrossRefPubMed
63.
go back to reference Wong BCY, Wong WM, Cheung KL, et al. A sensitive guaiac faecal occult blood test is less useful than an immunochemical test for colorectal cancer screening in a Chinese population. Aliment Pharmacol Ther. 2003;18:941–6.CrossRefPubMed Wong BCY, Wong WM, Cheung KL, et al. A sensitive guaiac faecal occult blood test is less useful than an immunochemical test for colorectal cancer screening in a Chinese population. Aliment Pharmacol Ther. 2003;18:941–6.CrossRefPubMed
64.
go back to reference Allison JE, Sakoda LC, Levin TR, et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst. 2007;99:1462–70.CrossRefPubMed Allison JE, Sakoda LC, Levin TR, et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst. 2007;99:1462–70.CrossRefPubMed
65.
go back to reference Cheng T-I, Wong J-M, Hong C-F, et al. Colorectal cancer screening in asymptomaic adults: comparison of colonoscopy, sigmoidoscopy and fecal occult blood tests. Taiwan Yi Xue Hui Za Zhi. 2002;101:685–90. Cheng T-I, Wong J-M, Hong C-F, et al. Colorectal cancer screening in asymptomaic adults: comparison of colonoscopy, sigmoidoscopy and fecal occult blood tests. Taiwan Yi Xue Hui Za Zhi. 2002;101:685–90.
66.
go back to reference Mandel JS, Bond JH, Bradley M, et al. Sensitivity, specificity, and positive predictivity of the Hemoccult test in screening for colorectal cancers. The University of Minnesota's Colon Cancer Control Study. Gastroenterology. 1989;97:597–600.PubMed Mandel JS, Bond JH, Bradley M, et al. Sensitivity, specificity, and positive predictivity of the Hemoccult test in screening for colorectal cancers. The University of Minnesota's Colon Cancer Control Study. Gastroenterology. 1989;97:597–600.PubMed
67.
go back to reference Heijenbrok-Kal MH, Hunink MGM. Adjusting for bias in diagnostic reports. Am J Med. 2002;112:322–4.CrossRefPubMed Heijenbrok-Kal MH, Hunink MGM. Adjusting for bias in diagnostic reports. Am J Med. 2002;112:322–4.CrossRefPubMed
68.
go back to reference Heresbach D, Manfredi S, D'Halluin PN, Bretagne J-F, Branger B. Review in depth and meta-analysis of controlled trials on colorectal cancer screening by faecal occult blood test. Eur J Gastroenterol Hepatol. 2006;18:427–33.CrossRefPubMed Heresbach D, Manfredi S, D'Halluin PN, Bretagne J-F, Branger B. Review in depth and meta-analysis of controlled trials on colorectal cancer screening by faecal occult blood test. Eur J Gastroenterol Hepatol. 2006;18:427–33.CrossRefPubMed
69.
go back to reference Towler B, Irwig L, Glasziou P, Kewenter J, Weller D, Silagy C. A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, hemoccult. Br Med J. 1998;317:559–65. Towler B, Irwig L, Glasziou P, Kewenter J, Weller D, Silagy C. A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, hemoccult. Br Med J. 1998;317:559–65.
70.
go back to reference Ransohoff DF, Lang CA. Screening for colorectal cancer with the fecal occult blood test: a background paper. Ann Intern Med. 1997;126:811–22.PubMed Ransohoff DF, Lang CA. Screening for colorectal cancer with the fecal occult blood test: a background paper. Ann Intern Med. 1997;126:811–22.PubMed
71.
go back to reference Screening for colorectal cancer: U.S.Preventive Services Task Force recommendation statement. Ann Intern Med 2008;149:627-37. Screening for colorectal cancer: U.S.Preventive Services Task Force recommendation statement. Ann Intern Med 2008;149:627-37.
72.
go back to reference Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin. 2008;58:130–60.CrossRefPubMed Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin. 2008;58:130–60.CrossRefPubMed
73.
go back to reference Davila RE, Rajan E, Baron TH, et al. ASGE guideline: colorectal cancer screening and surveillance. Gastrointest Endosc. 2006;63:546–57.CrossRefPubMed Davila RE, Rajan E, Baron TH, et al. ASGE guideline: colorectal cancer screening and surveillance. Gastrointest Endosc. 2006;63:546–57.CrossRefPubMed
74.
go back to reference Rex DK, Johnson DA, Anderson JC, et al. American College of Gastroenterology guidelines for colorectal cancer screening 2008. Am J Gastroenterol. 2009;104:739–50.CrossRefPubMed Rex DK, Johnson DA, Anderson JC, et al. American College of Gastroenterology guidelines for colorectal cancer screening 2008. Am J Gastroenterol. 2009;104:739–50.CrossRefPubMed
Metadata
Title
Effect of Verification Bias on the Sensitivity of Fecal Occult Blood Testing: a Meta-Analysis
Authors
Alan S. Rosman, MD
Mark A. Korsten, MD
Publication date
01-11-2010
Publisher
Springer-Verlag
Published in
Journal of General Internal Medicine / Issue 11/2010
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-010-1375-0

Other articles of this Issue 11/2010

Journal of General Internal Medicine 11/2010 Go to the issue

Healing Arts: Materia Medica

Six Words

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine